{"organizations": [], "uuid": "b71b85b61445c99777b4cfc57a0d12e41be8559d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000551/device/rss", "section_title": "California", "url": "https://www.cnbc.com/2018/05/09/the-associated-press-adverum-biotechnologies-1q-earnings-snapshot.html", "country": "US", "domain_rank": 767, "title": "Adverum Biotechnologies: 1Q Earnings Snapshot", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-10T00:17:00.000+03:00", "replies_count": 0, "uuid": "b71b85b61445c99777b4cfc57a0d12e41be8559d"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/05/09/the-associated-press-adverum-biotechnologies-1q-earnings-snapshot.html", "ord_in_thread": 0, "title": "Adverum Biotechnologies: 1Q Earnings Snapshot", "locations": [], "entities": {"persons": [], "locations": [{"name": "menlo park", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}, {"name": "menlo park", "sentiment": "none"}], "organizations": [{"name": "adverum biotechnologies inc.", "sentiment": "negative"}, {"name": "advm", "sentiment": "negative"}, {"name": "ap", "sentiment": "negative"}, {"name": "zacks investment research", "sentiment": "none"}, {"name": "adverum biotechnologies", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "MENLO PARK, Calif. (AP) _ Adverum Biotechnologies Inc. (ADVM) on Wednesday reported a loss of $17.2 million in its first quarter.\nThe Menlo Park, California-based company said it had a loss of 30 cents per share.\nThe results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 29 cents per share.\nThe gene therapy company posted revenue of $216,000 in the period.\nAdverum Biotechnologies shares have climbed 67 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $5.85, more than doubling in the last 12 months.\nThis story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on ADVM at https://www.zacks.com/ap/ADVM", "external_links": ["https://www.zacks.com/ap/ADVM", "http://automatedinsights.com/ap"], "published": "2018-05-10T00:17:00.000+03:00", "crawled": "2018-05-10T00:32:44.000+03:00", "highlightTitle": ""}